The embodiments herein are concerned with methods and hCVF compositions, including pharmaceutical formulations, useful in complement depletion, the reduction or prevention of unwanted immunogenicity or other immune-related reactions, especially as a consequence of administering a biologic therapy. Such methods and compositions have been found to be effective in complement depletion during more than one administration in the same subject, thereby being useful for prolonged/repeated use.